Pembrolizumab Dosing
The recommended dose of pembrolizumab for adults is 200 mg intravenously every 3 weeks OR 400 mg intravenously every 6 weeks, administered as a 30-minute infusion until disease progression, unacceptable toxicity, or up to 24 months depending on indication. 1
Standard Dosing Regimens
The FDA-approved dosing schedules are 1:
- 200 mg IV every 3 weeks (standard regimen)
- 400 mg IV every 6 weeks (alternative regimen)
- Pediatric patients: 2 mg/kg (up to 200 mg) IV every 3 weeks
Both adult regimens provide equivalent drug exposure and clinical efficacy across all approved indications including melanoma, NSCLC, HNSCC, urothelial cancer, MSI-H/dMMR cancers, gastric cancer, esophageal cancer, cervical cancer, HCC, RCC, endometrial carcinoma, and TNBC 1.
Body Weight Considerations
No dose adjustment is required for patients >120 kg. The flat dosing strategy (200 mg Q3W or 400 mg Q6W) was specifically designed to achieve target saturation regardless of body weight 2. Pharmacokinetic modeling demonstrated that:
- The 200 mg Q3W flat dose achieves ≥90% target engagement in clinically relevant scenarios across the weight spectrum 2
- Weight-based dosing (2 mg/kg Q3W) and flat dosing show comparable target engagement 3
- Randomized studies confirmed similar efficacy over a 5-fold dose/exposure range, validating the flat dosing approach 2, 4
Renal Impairment
No dose adjustment is required for renal impairment of any severity. Pembrolizumab is a monoclonal antibody that undergoes catabolism rather than renal elimination 5. The pharmacokinetic profile is not significantly altered by renal dysfunction, and dose modifications based on renal function are not necessary.
Hepatic Impairment
No dose adjustment is required for mild hepatic impairment. For moderate to severe hepatic impairment, data are limited, but no formal dose adjustment is recommended in the FDA label 1. Pembrolizumab, as a large molecule antibody, is not primarily metabolized by hepatic enzymes 5. However, baseline liver function should be monitored, and dose modifications may be needed if immune-mediated hepatitis develops during treatment.
Administration Details
- Infusion time: 30 minutes 1
- Preparation: Dilute before administration
- Duration of therapy: Until disease progression, unacceptable toxicity, or maximum 24 months for most indications (some adjuvant settings specify 12 months) 1
Indication-Specific Considerations
Adjuvant NSCLC
- 200 mg Q3W or 400 mg Q6W for up to 1 year following adjuvant chemotherapy 6
- For patients who received neoadjuvant pembrolizumab + chemotherapy: continue for up to 39 weeks postoperatively 6
Neoadjuvant + Adjuvant Melanoma
- Neoadjuvant: Maximum 3 cycles of 200 mg Q3W before surgery
- Adjuvant: Maximum 15 cycles of 200 mg Q3W after surgery 7
Metastatic Disease
- 200 mg Q3W or 400 mg Q6W until progression or unacceptable toxicity 7
Clinical Equivalence of Dosing Schedules
The 400 mg Q6W regimen was approved based on pharmacokinetic modeling showing 4:
- Similar average steady-state concentration (Cavg,ss) to 200 mg Q3W
- <1% of patients experience transiently lower trough concentrations
- Peak concentrations remain substantially below the maximum tested dose (10 mg/kg Q2W)
- Real-world data from 718 NSCLC patients confirmed no overall survival difference between Q3W and Q6W dosing (HR 0.759, p=0.230) 3
Key Monitoring Parameters
Assess at baseline and periodically during treatment 1:
- Liver enzymes (AST, ALT, bilirubin)
- Serum creatinine
- Thyroid function (TSH, free T4)
Critical caveat: The Q6W regimen offers equivalent efficacy with less frequent healthcare visits, improving patient convenience without compromising outcomes 3. This is particularly valuable for patients with transportation challenges or those seeking to minimize healthcare system interactions.